Entrada Therapeutics Inc (NASDAQ: TRDA) is -52.98% lower on its value in year-to-date trading and has touched a low of $7.10 and a high of $21.79 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The TRDA stock was last observed hovering at around $7.86 in the last trading session, with the day’s gains setting it 0.27%.
Currently trading at $8.13, the stock is -7.08% and -23.14% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.16 million and changing 3.44% at the moment leaves the stock -45.92% off its SMA200. TRDA registered -36.08% loss for a year compared to 6-month loss of -53.62%. The firm has a 50-day simple moving average (SMA 50) of $10.5779 and a 200-day simple moving average (SMA200) of $15.031975.
The stock witnessed a -24.37% gain in the last 1 month and extending the period to 3 months gives it a -35.17%, and is 3.57% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.73% over the week and 7.44% over the month.
Entrada Therapeutics Inc (TRDA) has around 183 employees, a market worth around $305.64M and $210.78M in sales. Current P/E ratio is 4.27. Profit margin for the company is 31.13%. Distance from 52-week low is 14.51% and -62.69% from its 52-week high. The company has generated returns on investments over the last 12 months (13.66%).
with sales reaching $10.17M over the same period.The EPS is expected to shrink by -302.85% this year, but quarterly earnings will post -82.60% year-over-year. Quarterly sales are estimated to shrink -82.80% in year-over-year returns.
159.0 institutions hold shares in Entrada Therapeutics Inc (TRDA), with institutional investors hold 99.54% of the company’s shares. The shares outstanding are 37.57M, and float is at 22.00M with Short Float at 5.30%. Institutions hold 82.10% of the Float.
The top institutional shareholder in the company is BAKER BROS. ADVISORS LP with over 4.87 million shares valued at $69.34 million. The investor’s holdings represent 14.2356 of the TRDA Shares outstanding. As of 2024-06-30, the second largest holder is MPM ASSET MANAGEMENT LLC with 4.43 million shares valued at $63.07 million to account for 12.9483 of the shares outstanding. The other top investors are 5AM VENTURE MANAGEMENT, LLC which holds 4.41 million shares representing 12.8973 and valued at over $62.82 million, while PRICE T ROWE ASSOCIATES INC /MD/ holds 9.3574 of the shares totaling 3.13 million with a market value of $44.67 million.
Entrada Therapeutics Inc (TRDA) Insider Activity
The most recent transaction is an insider sale by WENTWORTH KORY JAMES, the company’s Chief Financial Officer. SEC filings show that WENTWORTH KORY JAMES sold 1,784 shares of the company’s common stock on Mar 17 ’25 at a price of $10.67 per share for a total of $19035.0. Following the sale, the insider now owns 0.11 million shares.
Still, SEC filings show that on Dec 10 ’24, MPM BIOVENTURES 2018, L.P. (10% Owner) disposed off 22,935 shares at an average price of $20.77 for $0.48 million. The insider now directly holds 4,402,849 shares of Entrada Therapeutics Inc (TRDA).
